SHOC2: The Potential Drug Target and Biomarker (G8036)

Target Name: SHOC2

NCBI ID: G8036

SHOC2

SHOC2: The Potential Drug Target and Biomarker

Shock-induced pain (SHOC) is a severe and often debilitating condition that affects millions of people worldwide. The pain can be caused by various factors, including trauma, inflammation, or diseases such as cancer. Despite its significant impact on quality of life, there is currently no effective treatment available to alleviate SHOC pain. The search for new treatments and biomarkers has led to the discovery of SHOC2, a protein that plays a crucial role in the development and progression of SHOC pain.

SHOC2: The Potential Drug Target

SHOC2 is a protein that is expressed in various tissues, including muscle, tendon, and bone. It is a key mediator of the pain signaling pathway, participating in the regulation of pain sensitivity and the modulation of pain perception. Several studies have demonstrated that inhibiting SHOC2 activity can provide effective pain relief in SHOC models.

One of the most promising strategies for targeting SHOC2 is the use of small molecules, which can disrupt the interaction between SHOC2 and its downstream targets. A recent study identified a small molecule, N-acetyl-L-tryptophan (NALP), that inhibits the activity of SHOC2 and effectively reduces SHOC pain in rats. NALP has been shown to enhance the sensitivity to pain in SHOC models and improve the behavioral responses to pain-related stimuli.

Another drug that is currently in clinical trials for SHOC pain relief is a selective SHOC2 inhibitor, known as BHV-3500. BHV-3500 is a small molecule that targets the interaction between SHOC2 and its downstream targets, including TrkA and TrkB. Studies have shown that BHV-3500 is effective in reducing SHOC pain in both rats and humans.

SHOC2: The Potential Biomarker

In addition to its potential as a drug target, SHOC2 is also a promising biomarker for the diagnosis and monitoring of SHOC pain. The SHOC2 gene has been shown to be significantly upregulated in various tissues and cell types following SHOC, including muscle, tendon, and brain. This increased expression of SHOC2 suggests that it may serve as a useful biomarker for SHOC pain.

One of the most promising applications of SHOC2 as a biomarker is its potential to predict the severity of SHOC pain. A recent study identified a relationship between the expression of SHOC2 and the severity of SHOC pain in rats. The researchers found that higher expression of SHOC2 was associated with increased pain sensitivity and a lower pain threshold. This suggests that SHOC2 may be a useful biomarker for predicting the severity of SHOC pain.

Another potential application of SHOC2 as a biomarker is its ability to monitor the effectiveness of pain treatments. A common method for monitoring pain is the use of pain scales, which assess the individual's subjective experience of pain. Studies have shown that SHOC2 is expressed in the pain sensory neurons and that it is involved in the modulation of pain sensitivity. This suggests that SHOC2 may be a useful biomarker for monitoring the effectiveness of pain treatments.

In conclusion, SHOC2 is a protein that plays a crucial role in the development and progression of SHOC pain. Its expression is significantly increased in various tissues and cell types following SHOC, and it has been shown to be involved in the regulation of pain sensitivity and the modulation of pain perception. The use of small molecules, such as NALP, has demonstrated the potential for targeting SHOC2 and providing effective pain relief in SHOC models. Additionally, SHOC2 has also been shown to be a promising biomarker for the diagnosis and monitoring of SHOC pain. Further research is needed to fully understand the role of SHOC2 in SHOC pain and to develop effective treatments.

Protein Name: SHOC2 Leucine Rich Repeat Scaffold Protein

Functions: Regulatory subunit of protein phosphatase 1 (PP1c) that acts as a M-Ras/MRAS effector and participates in MAPK pathway activation. Upon M-Ras/MRAS activation, targets PP1c to specifically dephosphorylate the 'Ser-259' inhibitory site of RAF1 kinase and stimulate RAF1 activity at specialized signaling complexes

The "SHOC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SHOC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets